300108 Stock Overview
Engages in the research and development, production, and wholesale of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ji Yao Holding Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.56 |
| 52 Week High | CN¥3.90 |
| 52 Week Low | CN¥0.83 |
| Beta | 0.35 |
| 11 Month Change | 8.02% |
| 3 Month Change | 43.02% |
| 1 Year Change | -29.28% |
| 33 Year Change | -25.15% |
| 5 Year Change | -31.73% |
| Change since IPO | -52.18% |
Recent News & Updates
Shareholder Returns
| 300108 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -10.2% | -1.5% | -2.1% |
| 1Y | -29.3% | -9.4% | 2.8% |
Return vs Industry: 300108 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 300108 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 300108 volatility | |
|---|---|
| 300108 Average Weekly Movement | 12.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300108's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300108's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,065 | Zhengfa Lu | www.jiyaogroup.com |
Ji Yao Holding Group Co., Ltd. engages in the research and development, production, and wholesale of pharmaceutical products. It offers Chinese and western medicines.
Ji Yao Holding Group Co., Ltd. Fundamentals Summary
| 300108 fundamental statistics | |
|---|---|
| Market cap | CN¥1.70b |
| Earnings (TTM) | -CN¥436.44m |
| Revenue (TTM) | CN¥362.94m |
4.7x
P/S Ratio-3.9x
P/E RatioIs 300108 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300108 income statement (TTM) | |
|---|---|
| Revenue | CN¥362.94m |
| Cost of Revenue | CN¥261.30m |
| Gross Profit | CN¥101.64m |
| Other Expenses | CN¥538.08m |
| Earnings | -CN¥436.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 28.00% |
| Net Profit Margin | -120.25% |
| Debt/Equity Ratio | -122.0% |
How did 300108 perform over the long term?
See historical performance and comparison